During Q3, Bionano Genomics's (NASDAQ:BNGO) reported sales totaled $2.20 million. Despite a 37.55% in earnings, the company posted a loss of $10.23 million. Bionano Genomics collected $1.18 million in revenue during Q2, but reported earnings showed a $7.43 million loss.
What Is ROCE?
Changes in earnings and sales indicate shifts in Bionano Genomics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Bionano Genomics posted an ROCE of -0.7%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Bionano Genomics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.
Q3 Earnings Recap
Bionano Genomics reported Q3 earnings per share at $-0.08/share, which did not meet analyst predictions of $-0.05/share.
在第三季度,Bionano基因公司(納斯達克市場代碼:BNGO)報告的總銷售額為220萬美元。儘管該公司盈利37.55%,但仍虧損1,023萬美元。生物納米基因組公司第二季度營收為118萬美元,但公佈的收益顯示虧損743萬美元。
什麼是ROCE?
收益和銷售額的變化表明Bionano Genonomy的已用資本回報率發生了變化,這是一種衡量年度税前利潤相對於企業所用資本的指標。一般來説,較高的淨資產收益率意味着公司的成功增長,也是未來每股收益較高的跡象。在第三季度,Bionano基因組公司公佈的淨資產收益率為-0.7%。
重要的是要記住,ROCE評估的是過去的績效,而不是用作預測工具。這是衡量一家公司近期表現的一個很好的指標,但有幾個因素可能會在不久的將來影響收益和銷售額。
資本回報率是衡量效率的重要指標,也是比較同行業公司的有用工具。相對較高的ROCE表明,一家公司可能正在產生利潤,這些利潤可以再投資於更多資本,從而為股東帶來更高的回報和不斷增長的每股收益。
對於Bionano Genonomy來説,資本回報率表明,目前的資產規模實際上可能並沒有幫助公司實現更高的回報,許多投資者在做出長期財務決策時會考慮這一點。
第三季度收益摘要
BioNano Genology公佈第三季度每股收益為-0.08美元,低於分析師預測的-0.05美元。